Skip to main content

Table 1 Demographics, ankylosing spondylitis (AS)-related inflammatory diseases, and pharmacological treatment in cases and controls

From: Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study

Demographics Cases (n = 2453) Controls (n = 10,257)
Men, n (%) 1569 (64) 6587 (64)
Year of birth, median (min–max) 1971 (1964–1992) 1971 (1964–1992)
Age at first SpA-diagnosis (years), mean, SD (min–max) 30, 6.2 (17–46) 30, 6.2 (17–46)
AS-related inflammatory diseasesa
 Iridocyclitis, n (%) 453 (19) 45 (0)
 Inflammatory bowel disease, n (%) 102 (4) 37 (0)
 Psoriasis, n (%) 122 (5) 79 (1)
Pharmacological treatment in 2011b
 NSAID, n (%) 1279 (52) 9 (0)
 TNF inhibitor, n (%) 553 (23) NAc
 Methotrexate, n (%) 169 (7) 0
 Sulphasalazine, n (%) 263 (11) 1 (0)
  1. aAS-related inflammatory diseases are given as cumulative incidence until 2 years after first AS diagnosis for the cases and their matched controls
  2. bBased on prescriptions in the prescribed drugs register during 2011, apart from the tumour necrosis factor alpha (TNF) inhibitor infliximab for which data were based on recorded treatment in the Swedish Rheumatology Quality Register (SRQ) during 2011
  3. cTotal TNF inhibitor exposure was not possible to determine for controls since treatment with infliximab for nonrheumatic diseases cannot be detected through either the prescribed drugs register or SRQ. The frequency of any subcutaneous TNF inhibitors for controls during 2011 was n = 2
  4. NA Not available, NSAID nonsteroidal anti-inflammatory drug, SpA spondyloarthritis